{"filing":{"accession_number":"0001213900-26-094174","cik":"0001500198","ticker":"NMTC","company_name":"NEUROONE MEDICAL TECHNOLOGIES Corp","form":"8-K","filing_date":"2026-08-27","report_date":"2026-08-27","primary_document":"ea0303530-8k_neuroone.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1500198/000121390026094174/ea0303530-8k_neuroone.htm"},"events":[{"id":29947,"run_id":27448,"accession_number":"0001213900-26-094174","anchor_item_number":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"The filing discloses successful completion of three large-animal procedures using NeuroOne's StereoCED™ platform, demonstrating technical feasibility and a novel combination of drug delivery and electrophysiological recording. The company expects to recognize related revenue in fiscal Q4 2026 and plans to launch the platform for human investigational clinical studies later in the quarter. This represents a material operational and product development milestone for a medical device company, though it does not fit neatly into the specific operational categories (it is not a contract, partnership, or restructuring). The revenue recognition expectation and clinical launch timeline make this material to investors assessing the company's progress toward commercialization.","company_name":"NEUROONE MEDICAL TECHNOLOGIES Corp","ticker":"NMTC","filing_date":"2026-08-27","form":"8-K","submitted_at":null,"items":null}],"classifications":[{"id":32406,"accession_number":"0001213900-26-094174","item_number":null,"item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"The filing discloses successful completion of three large-animal procedures using NeuroOne's StereoCED™ platform, demonstrating technical feasibility and a novel combination of drug delivery and electrophysiological recording. The company expects to recognize related revenue in fiscal Q4 2026 and plans to launch the platform for human investigational clinical studies later in the quarter. This represents a material operational and product development milestone for a medical device company, though it does not fit neatly into the specific operational categories (it is not a contract, partnership, or restructuring). The revenue recognition expectation and clinical launch timeline make this material to investors assessing the company's progress toward commercialization.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-27T13:06:43.994501+00:00","company_name":"NEUROONE MEDICAL TECHNOLOGIES Corp","ticker":"NMTC","filing_date":"2026-08-27"}]}